share price, page-5

Hi Jeroe,
Just a few snippets that may help.

Not really sure where the trial stands at this point but probably a bit ambitious to expect revenue at this early stage.

Nomura Research Equities: Nov 2011
Action: MSB has been FDA approved to start a Phase III trial for bone-marrow transplantation.
We believe the trial should run for 12 months, with results available 3-6 months after that. These timelines are within our forecasts for timing of potential revenues for MSB.
We continue to forecast first potential sales for MSB from bone-marrow transplant in FY14.

Jefferies Annual Healthcare Conference
New York 2012
Bone Marrow Transplant Cord Blood Product:
Non-core niche market, FDA-cleared Phase 3 program
EU is the major transplant market, plan for early EU regulatory approval by Q1 2013

Mesoblast
Major Accomplishments
Key operational highlights of the 2011 year:
?Commenced our first Phase 3 trial, for bone marrow transplantation

Australian Stock Report: Oct 2011
Bone marrow approval

Mesoblast recently received approval from US authorities to begin an advanced trial of a treatment that could boost the number of bone marrow transplants for patients who cannot find a matched donor.

Following the approval, MSB has commenced the Phase III trial for bone marrow regeneration in patients with blood cancers.

MSB aims to produce a product that can be used in bone marrow transplants where a perfectly matched donor cannot be found.


Bell Potter 2011
MSB has five Phase II trials underway and is initiating a Phase III trial in Bone Marrow Transplant, with a revenue
opportunity matching that of Cochlear. With the FDA requiring only one Phase II and a pivotal trial before approving a successful stem cell therapy, the company has the potential to be yielding commercial revenues by late 2013.